

I. AMENDMENT

Amendment to the Claims:

The following listing of claims replaces all previous listings or versions thereof:

Listing of the Claims:

Please amend the claims by replacing them with the following listing of claims, which will replace all prior versions and listings of claims in the application.

1. (Currently Amended) A method for modulating cell death in a cell comprising contacting said cell with a[[n]] Spi2A-polypeptide comprising at least 5 consecutive amino acids of SEQ ID NO:2 or an Spi2A-polypeptide equivalent, wherein cell death is modulated in the cell.
2. (Currently Amended) The method of claim 1, wherein ~~the cell is contacted with an Spi2A~~ said polypeptide comprises at least 10 consecutive amino acids of SEQ ID NO:2.
3. (Withdrawn) The method of claim 1, wherein the cell is contacted with an Spi2A polypeptide equivalent.
4. (Withdrawn) The method of claim 3, wherein the Spi2A polypeptide equivalent is a polypeptide from Serpin B1, Serpin B2, Serpin B3, Serpin B4, Serpin B6, Serpin B8, or Serpin B9.
5. (Withdrawn) The method of claim 4, wherein the Spi2A polypeptide equivalent is a polypeptide from Serpin B9.
6. (Currently Amended) The method of claim 1, wherein the Spi2A-polypeptide ~~or Spi2A polypeptide equivalent is a polypeptide comprising~~ [[4]] comprises at least 5 to 8 consecutive amino acid residues of the amino acid sequences MAGVGCCA (SEQ ID NO:10) or FVVAECCM (SEQ ID NO:11).
- 7-11. (Canceled)

12. (Currently Amended) The method of claim 1, further defined as a method of modulating apoptosis, wherein apoptosis of the cell is modulated.
13. (Original) The method of claim 1, wherein said cell is a T lymphocyte.
14. (Original) The method of claim 12, wherein said method is further defined as a method for facilitating the differentiation of said lymphocyte into a memory T lymphocyte.
15. (Original) The method of claim 14, further defined as a method of promoting the development of an immune response in a subject against a target cell.
16. (Currently Amended) The method of claim 1, wherein the ~~SpizA~~-polypeptide or ~~SpizA~~ polypeptide equivalent is comprised in a vaccine.
17. (Original) The method of claim 15, wherein the target cell is a tumor cell or a cell that is infected by a pathogen.
- 18-20. (Canceled)
21. (Original) The method of claim 12, wherein said apoptosis is apoptosis due to increased lysosomal permeability in said cell.
22. (Original) The method of claim 21, wherein said increased lysosomal permeability results in release of at least one lysosomal protease within said cell.
23. (Original) The method of claim 22, wherein said lysosomal protease is a cysteine protease.
24. (Canceled)
25. (Original) The method of claim 1, further defined as a method of modulating autophagic cell death.

26. (Original) The method of claim 1, further defined as a method of modulating $\text{TNF-}\alpha$ – mediated cell death.
27. (Original) The method of claim 1, further defined as a method of modulating cell death due to reactive oxygen species within said cell.
28. (Original) The method of claim 1, further defined as a method of modulating cell death due to necrosis.
29. (Original) The method of claim 1, wherein said cell is in a subject.
30. (Original) The method of claim 29, wherein said subject is a human.
31. (Original) The method of claim 30, wherein said human is a patient with an infection.
32. (Canceled)
33. (Original) The method of claim 31, wherein the infection is an infection due to a biological weapon.
34. (Canceled)
35. (Original) The method of claim 30, wherein said human is a patient with septic shock.
36. (Original) The method of claim 30, wherein said human is a patient with hepatic failure.
37. (Original) The method of claim 36, wherein the hepatic failure is fulminating hepatic failure.
38. (Canceled)
39. (Original) The method of claim 30, wherein said human is a patient with an inflammatory disease.

40. (Original) The method of claim 39, wherein the inflammatory disease is liver disease.
- 41-45. (Canceled)
46. (Original) The method of claim 30, wherein said human is a patient with vascular disease.
- 47-48. (Canceled)
49. (Previously Presented) The method of claim 46, wherein said vascular disease is a myocardial infarction.
50. (Original) The method of claim 30, wherein said human is a patient with cancer.
51. (Original) The method of claim 30, wherein said human is a patient with a bone disease.
52. (Original) The method of claim 51, wherein the bone disease is osteoporosis.
- 53-55. (Canceled)
56. (Original) The method of claim 30, wherein said human is a patient with a viral infection.
- 57-58. (Canceled)
59. (Original) The method of claim 58, wherein said immune disorder is an autoimmune disorder.
60. (Canceled)
61. (Original) The method of claim 30, wherein said human is a patient with multiple sclerosis.

62. (Canceled)

63. (Original) The method of claim 30, wherein said human is a patient with arthritis.

64. (Original) The method of claim 63, wherein said patient with arthritis is a patient with rheumatoid arthritis.

65-204. (Canceled)

205. (New) The method of claim 2, wherein said polypeptide comprises at least the full-length sequence set forth in SEQ ID NO:2.